Mumbai-based Glenmark Pharmaceuticals has also introduced a generic drug of Empagliflozin under the brand name Glempa, along with its fixed-dose combinations Glempa-L and Glempa-M. Alok Malik, ...

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed ...

Mumbai-based Glenmark Pharmaceuticals has also introduced a generic drug of Empagliflozin under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations Glempa-L ...

Glenmark Pharmaceuticals also launched the drug and said its version of the SGLT2 inhibitor product was being launched as Glempa, and in multiple strengths - Empagliflozin 10/25 mg, besides fixed-dose ...

The New Zealand Government is set to introduce significant changes to the country’s tax rules, aiming to foster investment and attract skilled professionals, according to Revenue Minister Simon Watts.

Glenmark Pharmaceuticals has introduced Glempa, a medication designed for glycemic control and weight-loss in type 2 diabetes patients. The drug, an SGLT2 inhibitor, aims to improve cardiovascular ...

The drug has been introduced under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)—Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M ...

Glenmark Pharmaceuticals announced today the launch of Empagliflozin and its fixed-drug combinations in India under the brand names Glempa, Glempa-L, and Glempa-M. The shares of Glenmark ...

Glenmark Pharmaceuticals launches Empagliflozin, an SGLT2 inhibitor, in India under the brand name Glempa for glycemic control and weight-loss in diabetes patients. New Delhi, Mar 12 (PTI) Glenmark ...